EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Targeting Folate Receptors for the Detection and Selective Treatment of Cancer: Advanced Precision Oncology in Practice

Michal Stark, Yehuda G Assaraf

International Journal of Biological Sciences · 30.07.2026 · 22 (13) · 7018-7052

DOI: 10.7150/ijbs.139733 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Biological Sciences, erschienen am 30.07.2026. Verfasst von Michal Stark und 1 weiteren Autor:innen. Beteiligte Einrichtung: The Fred Wyszkowski Cancer Research Laboratory, Faculty of Biology, The Technion-Israel Institute of Technology, Haifa 3200003, Israel. Hauptthemen laut MEDLINE: Neoplasms, Precision Medicine, Folate Receptor 1. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The modern era of precision oncology strives to identify novel and selective druggable targets that, on the one hand, achieve efficacious anti-tumor activity, and on the other hand inflict minimal adverse effects to healthy tissues.The realization that both the tumor microenvironment and the tumor immune microenvironment (TIME) modulate tumor progression and response to chemotherapeutics, has pushed tumor-associated immune cells to the forefront as bona fide druggable targets.Based on their unique overexpression pattern on the cell surface of specific human malignancies and suppressor immune cells, folate receptors FRα and FRβ constitute optimal facilitators of noninvasive cancer detection and localization, as well as efficacious selective delivery of potent therapeutic payloads.Along this vein, this review highlights recent advanced strategies utilizing FR-targeting for precise tumor and metastatic lesion localization for guided surgical precision resection, potent anti-cancer efficacy and reprogramming of the suppressive TIME.Notably, these activities were accomplished with minimal side effects to healthy tissues.AZD5335, a recent clinically tested FRα-targeted antibody-drug conjugate carrying a topoisomerase I inhibitor payload, exceeded its predecessors by demonstrating remarkable efficacy against low FRα-expressing tumors as well.Thus, FRs emerge as selective and promising targets for advanced precision oncology of various malignancies including those displaying chemoresistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsPrecision MedicineFolate Receptor 1HumansAnimalsTumor MicroenvironmentAntineoplastic Agents

Stichwörter der Autor:innen

cancer detectionfolate receptorselective targetingtumor associated macrophages

Substanzen

Folate Receptor 1Antineoplastic Agents

Autor:innen und Institutionen

  • The Fred Wyszkowski Cancer Research Laboratory, Faculty of Biology, The Technion-Israel Institute of Technology, Haifa 3200003, Israel.

Zitieren

APA

Stark, M., & Assaraf, Y. G. (2026). Targeting Folate Receptors for the Detection and Selective Treatment of Cancer: Advanced Precision Oncology in Practice. International Journal of Biological Sciences, 22(13), 7018-7052. https://doi.org/10.7150/ijbs.139733

Vancouver

Stark M, Assaraf YG. Targeting Folate Receptors for the Detection and Selective Treatment of Cancer: Advanced Precision Oncology in Practice. International Journal of Biological Sciences. 2026;22(13):7018-7052. doi:10.7150/ijbs.139733

BibTeX
@article{Stark2026,
  author = {Stark, Michal and Assaraf, Yehuda G},
  title = {Targeting Folate Receptors for the Detection and Selective Treatment of Cancer: Advanced Precision Oncology in Practice},
  journal = {International Journal of Biological Sciences},
  year = {2026},
  volume = {22},
  number = {13},
  pages = {7018--7052},
  doi = {10.7150/ijbs.139733}
}
Kostenlos starten →